How to diagnose familial hypercholesterolemia?

Reading File
Finding Sources
Searching PubMed

"familial hypercholesterolemia"[MeSH Terms] AND diagnosis

Searching Images

familial hypercholesterolemia xanthoma xanthelasma diagnosis

This composite clinical photograph displays multiple cutaneous manifestations of xanthomas in a patient with homozygous familial hypercholesterolemia. The image is divided into four panels, each highlighting a different anatomical region with arrows pointing to the pathology. Top left: Ocular region showing xanthelasma palpebrarum, characterized by yellowish, slightly raised plaques on the upper and lower eyelids. Top right: Bilateral patellar region demonstrating tuberous xanthomas, which appear as firm, yellowish-orange nodules over the knees. Bottom left: Posterior view of the ankle showing a prominent tendon xanthoma of the Achilles tendon, presenting as a large, subcutaneous nodular thickening. Bottom right: Cubital fossa/elbow region showing a tuberoeruptive xanthoma with a wrinkled, raised, yellowish appearance over the extensor surface. Collectively, these findings illustrate the systemic deposition of cholesterol-rich material in skin and tendons, serving as a hallmark diagnostic sign for severe primary hyperlipidemia and associated cardiovascular risk.

This composite clinical photograph displays multiple cutaneous manifestations of xanthomas in a patient with homozygous familial hypercholesterolemia. The image is divided into four panels, each highlighting a different anatomical region with arrows pointing to the pathology. Top left: Ocular region showing xanthelasma palpebrarum, characterized by yellowish, slightly raised plaques on the upper and lower eyelids. Top right: Bilateral patellar region demonstrating tuberous xanthomas, which appear as firm, yellowish-orange nodules over the knees. Bottom left: Posterior view of the ankle showing a prominent tendon xanthoma of the Achilles tendon, presenting as a large, subcutaneous nodular thickening. Bottom right: Cubital fossa/elbow region showing a tuberoeruptive xanthoma with a wrinkled, raised, yellowish appearance over the extensor surface. Collectively, these findings illustrate the systemic deposition of cholesterol-rich material in skin and tendons, serving as a hallmark diagnostic sign for severe primary hyperlipidemia and associated cardiovascular risk.

This is a gross pathology photograph of an excised tuberous xanthoma from an 18-year-old female with familial hypercholesterolemia (type IIa). The specimen shows a solitary, well-circumscribed, nodular lesion removed from periarticular soft tissue around a knee (and noted at elbows and toes in the clinical history). On gross inspection, the cut surface is homogeneously pale to yellow-orange, soft, and slightly lobulated, with a glossy, lipid-rich appearance consistent with lipid-laden macrophage infiltration. Histology is diagnostic of xanthoma, characterized by dense aggregates of foamy macrophages (lipid-laden histiocytes) in the dermis/subcutaneous tissue with accompanying chronic inflammatory infiltrate and varying degrees of fibrosis in long-standing lesions. The lipid-rich cytoplasm creates the characteristic yellow hue. Systemic findings include elevated total cholesterol and LDL cholesterol with normal triglycerides, VLDL, and HDL; thyroid function is normal. This phenotype corresponds to familial hypercholesterolemia, type IIa, typically due to LDL receptor or ApoB gene defects. Xanthomas are not neoplasms but reactive lipid deposits that reflect prolonged hyperlipidemia and local tissue remodeling. Clinically relevant implications include increased risk of premature atherosclerotic cardiovascular disease, guiding lipid-lowering therapy and family screening. Correlation with histologic confirmation supports diagnosis and informs genetic counseling, lifestyle modification, and pharmacotherapy, such as statins, PCSK9 inhibitors, or ezetimibe.

This is a gross pathology photograph of an excised tuberous xanthoma from an 18-year-old female with familial hypercholesterolemia (type IIa). The specimen shows a solitary, well-circumscribed, nodular lesion removed from periarticular soft tissue around a knee (and noted at elbows and toes in the clinical history). On gross inspection, the cut surface is homogeneously pale to yellow-orange, soft, and slightly lobulated, with a glossy, lipid-rich appearance consistent with lipid-laden macrophage infiltration. Histology is diagnostic of xanthoma, characterized by dense aggregates of foamy macrophages (lipid-laden histiocytes) in the dermis/subcutaneous tissue with accompanying chronic inflammatory infiltrate and varying degrees of fibrosis in long-standing lesions. The lipid-rich cytoplasm creates the characteristic yellow hue. Systemic findings include elevated total cholesterol and LDL cholesterol with normal triglycerides, VLDL, and HDL; thyroid function is normal. This phenotype corresponds to familial hypercholesterolemia, type IIa, typically due to LDL receptor or ApoB gene defects. Xanthomas are not neoplasms but reactive lipid deposits that reflect prolonged hyperlipidemia and local tissue remodeling. Clinically relevant implications include increased risk of premature atherosclerotic cardiovascular disease, guiding lipid-lowering therapy and family screening. Correlation with histologic confirmation supports diagnosis and informs genetic counseling, lifestyle modification, and pharmacotherapy, such as statins, PCSK9 inhibitors, or ezetimibe.

This composite of three clinical photographs displays classic dermatological manifestations of Familial Hypercholesterolemia (FH). Panel (a) shows bilateral Achilles tendon xanthomas, presenting as large, firm, rounded subcutaneous swellings at the posterior aspect of the heels that significantly distort the local anatomy. Panel (b) illustrates a tuberous xanthoma on the elbow, characterized by a large, well-circumscribed, flesh-colored to slightly yellowish nodular protrusion with a smooth overlying surface. Panel (c) shows the plantar aspect of the foot, demonstrating planar xanthomas that cause diffuse thickening and yellowish discoloration of the sole, along with a visible vertical surgical incision line with sutures. These findings are highly characteristic of severe hyperlipidemia, specifically FH, where lipid deposits accumulate in the skin and tendons. The images serve as an educational reference for identifying physical stigmata of lipid metabolism disorders in a clinical setting.

This composite of three clinical photographs displays classic dermatological manifestations of Familial Hypercholesterolemia (FH). Panel (a) shows bilateral Achilles tendon xanthomas, presenting as large, firm, rounded subcutaneous swellings at the posterior aspect of the heels that significantly distort the local anatomy. Panel (b) illustrates a tuberous xanthoma on the elbow, characterized by a large, well-circumscribed, flesh-colored to slightly yellowish nodular protrusion with a smooth overlying surface. Panel (c) shows the plantar aspect of the foot, demonstrating planar xanthomas that cause diffuse thickening and yellowish discoloration of the sole, along with a visible vertical surgical incision line with sutures. These findings are highly characteristic of severe hyperlipidemia, specifically FH, where lipid deposits accumulate in the skin and tendons. The images serve as an educational reference for identifying physical stigmata of lipid metabolism disorders in a clinical setting.

This composite of four clinical photographs (labeled A-D) illustrates the dermatological and musculoskeletal manifestations of Familial Hypercholesterolemia (FH) in a pediatric patient. Panel A displays large, bilateral, yellowish-tan cutaneous xanthomas on the buttocks and upper thighs, characterized by irregular borders and a plaque-like distribution. Panel B shows a distinct, yellowish-tan nodule with a roughened surface over the extensor surface of the elbow, consistent with a tuberous xanthoma. Panel C depicts the dorsal aspect of a hand with several small, raised, yellowish cutaneous xanthomas located on the fingers and interdigital webs. Panel D reveals a prominent, elongated yellowish nodule overlying the Achilles tendon, indicative of a tendinous xanthoma. Red arrows in each panel highlight the specific lesions. These clinical findings are hallmark physical signs of severe lipid metabolic disorders, representing localized accumulations of lipid-laden macrophages (foam cells) in the skin and tendons due to extreme hyperlipidemia.

This composite of four clinical photographs (labeled A-D) illustrates the dermatological and musculoskeletal manifestations of Familial Hypercholesterolemia (FH) in a pediatric patient. Panel A displays large, bilateral, yellowish-tan cutaneous xanthomas on the buttocks and upper thighs, characterized by irregular borders and a plaque-like distribution. Panel B shows a distinct, yellowish-tan nodule with a roughened surface over the extensor surface of the elbow, consistent with a tuberous xanthoma. Panel C depicts the dorsal aspect of a hand with several small, raised, yellowish cutaneous xanthomas located on the fingers and interdigital webs. Panel D reveals a prominent, elongated yellowish nodule overlying the Achilles tendon, indicative of a tendinous xanthoma. Red arrows in each panel highlight the specific lesions. These clinical findings are hallmark physical signs of severe lipid metabolic disorders, representing localized accumulations of lipid-laden macrophages (foam cells) in the skin and tendons due to extreme hyperlipidemia.

Reading File
Reading File
Reading File
Reading File
Reading File
Searching PubMed

"familial hypercholesterolemia" AND "Dutch Lipid Clinic" OR "Simon Broome" diagnosis criteria

Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
I now have comprehensive information from multiple authoritative textbooks. Let me compile a thorough answer.

Diagnosis of Familial Hypercholesterolemia (FH)

Familial hypercholesterolemia (FH) is an autosomal dominant disorder caused primarily by loss-of-function mutations in the LDL receptor (LDLR) gene (~80-90% of cases), with less common causes including APOB mutations (~5-10%) and PCSK9 gain-of-function mutations (<2%). It affects approximately 1 in 250 people worldwide, making it one of the most common single-gene disorders in humans.

1. Clinical Suspicion - When to Consider FH

FH should be suspected in:
  • Adults (≥20 years): LDL-C > 190 mg/dL (persistently elevated after ruling out secondary causes)
  • Children: LDL-C consistently elevated, especially with positive family history
  • Family history: First-degree relative with premature ASCVD (men <55 years, women <65 years) or very high LDL-C
  • Physical stigmata present at any age
Secondary causes that must first be excluded include hypothyroidism, nephrotic syndrome, cholestasis, diabetes, and drugs (glucocorticoids, cyclosporine, anticonvulsants).

2. Clinical Features (Physical Examination)

These findings strongly raise suspicion for FH:
FeatureDescriptionNotes
Tendinous xanthomasFirm, nodular cholesterol deposits in Achilles tendon, extensor tendons of hands/feetMost specific sign; pathognomonic in right clinical context
Tuberous/tuberoeruptive xanthomasYellow-orange nodules over knees, elbows, buttocksMore common in homozygous FH
Xanthelasma palpebrarumYellowish plaques on eyelidsLess specific - can occur in normolipidemia
Corneal arcusWhite/grey ring around corneaSignificant if present before age 45
Planar xanthomasFlat yellow deposits, especially interdigital websSuggest homozygous FH
In homozygous FH, xanthomas and ASCVD events can appear in childhood. In heterozygous FH, xanthomas appear in the second-third decade and premature CHD in men by the fourth decade.
Xanthomas in familial hypercholesterolemia - xanthelasma, tuberous xanthoma, Achilles tendon xanthoma, and tuberoeruptive xanthoma
Achilles tendon xanthoma, tuberous elbow xanthoma, and plantar xanthoma in FH

3. Laboratory Investigations

Primary test: Fasting lipid panel
ParameterHeterozygous FHHomozygous FH
LDL-C>190 mg/dL (typically >220 mg/dL)>400 mg/dL
Total cholesterolMarkedly elevatedSeverely elevated (often >600-700 mg/dL)
TriglyceridesUsually normal (key distinguishing feature)
HDL-CUsually normal
  • Apolipoprotein B-100 can be elevated
  • Elevated LDL-C from birth is characteristic; FH does not cause hypertriglyceridemia in isolation
Additional labs to exclude secondary causes: TSH (hypothyroidism), urinalysis/protein (nephrotic syndrome), liver function tests, fasting glucose.

4. Formal Diagnostic Criteria

Three well-established clinical scoring systems are used:

A. Dutch Lipid Clinic Network (DLCN) - Point-Based System

CategoryCriterionPoints
Family historyFirst-degree relative with tendinous xanthoma or premature ASCVD1-2
First-degree relative with known FH1
First-degree relative with LDL-C >95th percentile1
Clinical historyPatient has premature ASCVD (<55M / <60F)2
Patient has premature cerebrovascular or peripheral artery disease1
Physical examinationTendinous xanthoma6
Corneal arcus before age 454
LDL-C level≥8.5 mmol/L (≥328 mg/dL)8
6.5-8.4 mmol/L5
5.0-6.4 mmol/L3
4.0-4.9 mmol/L1
Genetic testingPathogenic LDLR, APOB, or PCSK9 mutation8
Score interpretation:
  • 8 points = Definite FH
  • 6-8 points = Probable FH
  • 3-5 points = Possible FH
  • <3 points = FH unlikely

B. Simon Broome Register (UK)

  • Definite FH: Total cholesterol >7.5 mmol/L (adults) or >6.7 mmol/L (children) AND tendinous xanthoma in patient or first-degree relative; OR DNA evidence of pathogenic LDLR/APOB mutation
  • Possible FH: Same cholesterol threshold PLUS family history of premature MI (<50 in 2 relatives; <60 in 1 relative) OR total cholesterol >7.5 mmol/L in a first/second-degree relative

C. US MEDPED Program (Make Early Diagnosis - Prevent Early Deaths)

Uses age-specific and relationship-specific cut-off levels for total cholesterol and LDL-C. Cut-off thresholds differ depending on whether the index case is a first-, second-, or third-degree relative versus the general population. For example, LDL-C thresholds are progressively lower as genetic proximity to a known FH case increases (the closer the relative, the lower the diagnostic threshold needed).

5. Genetic Testing

Genetic testing is increasingly favored because:
  • Definitively confirms the diagnosis when a pathogenic variant is found
  • Enables cascade screening of relatives (50% of first-degree relatives will be affected in autosomal dominant inheritance)
  • Guides treatment decisions (e.g., receptor-negative vs. receptor-defective status affects statin response in homozygous FH)
  • Required by some insurers for approval of PCSK9 inhibitors
Genes tested: LDLR (>2000 known LOF mutations), APOB (primarily R3500Q missense), PCSK9 (gain-of-function), and rarely LDLRAP1 (autosomal recessive FH).
Important limitation: A negative genetic test does not rule out FH - up to 20-40% of clinically diagnosed FH patients have no identifiable mutation with current panels.

6. Screening Strategy

PopulationRecommendation
General childrenUniversal fasting or non-fasting lipid panel between ages 8-11 years
High-risk childrenScreen earlier if family history of LDL-C >190 mg/dL or premature ASCVD
AdultsLipid panel by age 20 at the latest
Relatives of index caseCascade screening - screen all first-degree relatives once an index case is identified

7. Distinguishing Heterozygous vs. Homozygous FH

FeatureHeterozygous FHHomozygous FH
LDL-C190-400 mg/dL>400 mg/dL (often 600-1000 mg/dL)
ASCVD onset30s-40s (men), 40s-50s (women)Childhood
XanthomasLate 2nd-3rd decadeChildhood, sometimes at birth
LDLR activity~50% functional<2% (receptor negative) or 2-25% (receptor defective)
Statin responseGoodPoor (apheresis often needed)

Key References

  • Henry's Clinical Diagnosis and Management by Laboratory Methods, p. 303-304
  • Harrison's Principles of Internal Medicine 22E, p. 3286
  • Goldman-Cecil Medicine, Chapter 190
  • Thompson & Thompson Genetics and Genomics in Medicine, 9th ed., Table C.16.2
  • Tietz Textbook of Laboratory Medicine, 7th Edition, p. 1180
  • Robbins & Kumar Basic Pathology, p. 111

How to diagnose familial hypercholesterolemia?

Reading File
Finding Sources
Searching PubMed

"familial hypercholesterolemia"[MeSH Terms] AND diagnosis

Searching Images

familial hypercholesterolemia xanthoma tendon xanthelasma corneal arcus

This composite clinical photograph displays multiple cutaneous manifestations of xanthomas in a patient with homozygous familial hypercholesterolemia. The image is divided into four panels, each highlighting a different anatomical region with arrows pointing to the pathology. Top left: Ocular region showing xanthelasma palpebrarum, characterized by yellowish, slightly raised plaques on the upper and lower eyelids. Top right: Bilateral patellar region demonstrating tuberous xanthomas, which appear as firm, yellowish-orange nodules over the knees. Bottom left: Posterior view of the ankle showing a prominent tendon xanthoma of the Achilles tendon, presenting as a large, subcutaneous nodular thickening. Bottom right: Cubital fossa/elbow region showing a tuberoeruptive xanthoma with a wrinkled, raised, yellowish appearance over the extensor surface. Collectively, these findings illustrate the systemic deposition of cholesterol-rich material in skin and tendons, serving as a hallmark diagnostic sign for severe primary hyperlipidemia and associated cardiovascular risk.

This composite clinical photograph displays multiple cutaneous manifestations of xanthomas in a patient with homozygous familial hypercholesterolemia. The image is divided into four panels, each highlighting a different anatomical region with arrows pointing to the pathology. Top left: Ocular region showing xanthelasma palpebrarum, characterized by yellowish, slightly raised plaques on the upper and lower eyelids. Top right: Bilateral patellar region demonstrating tuberous xanthomas, which appear as firm, yellowish-orange nodules over the knees. Bottom left: Posterior view of the ankle showing a prominent tendon xanthoma of the Achilles tendon, presenting as a large, subcutaneous nodular thickening. Bottom right: Cubital fossa/elbow region showing a tuberoeruptive xanthoma with a wrinkled, raised, yellowish appearance over the extensor surface. Collectively, these findings illustrate the systemic deposition of cholesterol-rich material in skin and tendons, serving as a hallmark diagnostic sign for severe primary hyperlipidemia and associated cardiovascular risk.

This composite clinical photograph illustrates hallmark physical manifestations of Familial Hypercholesterolemia (FH). Panel A presents a posterior view of the ankles, demonstrating bilateral Achilles tendon thickening (tendon xanthoma), indicated by red arrows. Panel B shows the extensor surface of the elbow featuring cutaneous xanthomas, which appear as raised, yellowish, irregularly shaped plaques on the skin surface. Panel C provides a close-up clinical view of the eye, revealing arcus corneae (arcus senilis), characterized by a distinct grayish-white opaque ring or arc at the periphery of the cornea. These findings are classic clinical markers for severe hyperlipidemia, often associated with genetic mutations in the LDL receptor. The image serves as an educational tool for identifying the external stigmata of lipid metabolism disorders in a pediatric or adult patient.

This composite clinical photograph illustrates hallmark physical manifestations of Familial Hypercholesterolemia (FH). Panel A presents a posterior view of the ankles, demonstrating bilateral Achilles tendon thickening (tendon xanthoma), indicated by red arrows. Panel B shows the extensor surface of the elbow featuring cutaneous xanthomas, which appear as raised, yellowish, irregularly shaped plaques on the skin surface. Panel C provides a close-up clinical view of the eye, revealing arcus corneae (arcus senilis), characterized by a distinct grayish-white opaque ring or arc at the periphery of the cornea. These findings are classic clinical markers for severe hyperlipidemia, often associated with genetic mutations in the LDL receptor. The image serves as an educational tool for identifying the external stigmata of lipid metabolism disorders in a pediatric or adult patient.

A multi-panel clinical photograph collection documenting physical manifestations of homozygous familial hypercholesterolemia (HoFH) and the effects of lipoprotein apheresis. Image A shows arcus lipoides (corneal arcus), characterized by a hazy, whitish-gray lipid ring at the corneal periphery. Image B demonstrates tuberous xanthomas on the extensor surface of the elbow, appearing as firm, yellowish-orange nodules. Image C illustrates tendon xanthomas, specifically bilateral thickening and prominence of the Achilles tendons. Panels D-1 through D-3 provide a longitudinal view of cutaneous xanthomas on the extensor surface of the knee. D-1 shows multiple eruptive and tuberous xanthomas before starting apheresis. D-2 shows the progression after a three-year discontinuation of apheresis, with significant enlargement and confluence of the nodules. D-3 demonstrates near-complete resolution of the xanthomas following three years of regular apheresis, with only residual skin hyperpigmentation. These images collectively serve as educational material for the dermatological and ophthalmological signs of severe hyperlipidemia and the visible efficacy of lipid-lowering interventions.

A multi-panel clinical photograph collection documenting physical manifestations of homozygous familial hypercholesterolemia (HoFH) and the effects of lipoprotein apheresis. Image A shows arcus lipoides (corneal arcus), characterized by a hazy, whitish-gray lipid ring at the corneal periphery. Image B demonstrates tuberous xanthomas on the extensor surface of the elbow, appearing as firm, yellowish-orange nodules. Image C illustrates tendon xanthomas, specifically bilateral thickening and prominence of the Achilles tendons. Panels D-1 through D-3 provide a longitudinal view of cutaneous xanthomas on the extensor surface of the knee. D-1 shows multiple eruptive and tuberous xanthomas before starting apheresis. D-2 shows the progression after a three-year discontinuation of apheresis, with significant enlargement and confluence of the nodules. D-3 demonstrates near-complete resolution of the xanthomas following three years of regular apheresis, with only residual skin hyperpigmentation. These images collectively serve as educational material for the dermatological and ophthalmological signs of severe hyperlipidemia and the visible efficacy of lipid-lowering interventions.

Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
Reading File
Finding Sources
I now have comprehensive information from multiple authoritative textbooks. Here is the full structured answer:

Diagnosis of Familial Hypercholesterolemia (FH)

FH is one of the most common single-gene disorders in humans, affecting ~1 in 250 people worldwide. It is caused by mutations that reduce LDL receptor (LDLR) function, leading to lifelong elevation of LDL-cholesterol from birth. Diagnosis combines lipid values, physical findings, family history, and genetic testing.

Step 1 - Raise Clinical Suspicion

FH should be considered when:
  • An adult has LDL-C persistently >190 mg/dL with relatively normal triglycerides
  • A child has LDL-C consistently elevated (>95th percentile for age)
  • There is a family history of premature atherosclerotic cardiovascular disease (ASCVD) - defined as men <55 years or women <65 years in a first-degree relative
  • There is a family history of a first-degree relative with known FH or very high LDL-C (>190 mg/dL)
  • Physical stigmata are present (see below)
Before diagnosing FH, secondary causes of elevated LDL must be excluded:
Secondary CauseExamples
EndocrineHypothyroidism, Cushing syndrome, estrogen deficiency
RenalNephrotic syndrome, chronic kidney disease
HepaticBiliary obstruction
DrugsGlucocorticoids, cyclosporine, anticonvulsants, anabolic steroids, diuretics
MetabolicObesity, poorly controlled diabetes

Step 2 - Physical Examination

These findings are hallmarks of FH and carry significant diagnostic weight:
SignDescriptionSignificance
Tendinous xanthomasFirm cholesterol deposits in Achilles, patellar, and extensor tendons of handsMost specific; scored highest in Dutch criteria (6 pts)
Tuberous/tuberoeruptive xanthomasYellow-orange nodules over knees, elbows, buttocksMore prominent in homozygous FH
Xanthelasma palpebrarumYellowish plaques on eyelidsLess specific; can occur in normal lipidemia
Corneal arcusWhite-grey opaque ring at corneal peripherySignificant if present before age 45; scores 4 pts in Dutch criteria
Planar xanthomasFlat yellow deposits, including interdigital websSuggest homozygous FH when present in childhood
Note: A generation ago, these clinical signs were found in >50% of heterozygous FH patients. More recently, due to earlier detection and treatment, <20% of patients present with these features at diagnosis.
Composite clinical image showing xanthelasma, tuberous patellar xanthomas, Achilles tendon xanthoma, and tuberoeruptive elbow xanthoma in homozygous FH
Achilles tendon xanthomas, elbow xanthoma, and corneal arcus - three classic FH stigmata

Step 3 - Laboratory Investigations

Essential test: Fasting lipid panel
MarkerHeterozygous FHHomozygous FH
LDL-CUsually >190-220 mg/dL>400 mg/dL (often 600-1000 mg/dL)
Total cholesterolMarkedly elevatedSeverely elevated
TriglyceridesNormal - a key distinguishing featureNormal
HDL-CUsually normalUsually normal
The pattern of isolated LDL elevation with normal TG is characteristic. A pathogenic variant is found in >95% of patients with LDL-C >8 mmol/L (~309 mg/dL) referred to a lipid clinic.
Supporting tests: Apolipoprotein B-100 (elevated), TSH, urinalysis, renal/liver function (to exclude secondary causes)

Step 4 - Formal Clinical Diagnostic Criteria

Three established scoring systems are used:

A. Dutch Lipid Clinic Network (DLCN) - Most widely used

CategoryCriterionPoints
LDL-C level≥8.5 mmol/L (≥328 mg/dL)8
6.5-8.4 mmol/L5
5.0-6.4 mmol/L3
4.0-4.9 mmol/L1
Personal clinical historyPremature coronary artery disease (<55M / <60F)2
Premature cerebrovascular or peripheral artery disease1
Physical examinationTendinous xanthoma (patient)6
Corneal arcus before age 454
Family historyFirst-degree relative with tendinous xanthoma or premature ASCVD2
First-degree relative with LDL-C ≥7.5 mmol/L or FH1
Genetic testingPathogenic LDLR, APOB, or PCSK9 mutation8
Interpretation: >8 = Definite FH | 6-8 = Probable FH | 3-5 = Possible FH | <3 = Unlikely

B. Simon Broome Register (UK)

  • Definite FH: Total cholesterol >7.5 mmol/L in an adult (or >6.7 mmol/L in a child <16 years) AND either:
    • Tendinous xanthomas in the patient or a first- or second-degree relative, OR
    • DNA evidence of pathogenic LDLR, APOB, or PCSK9 mutation
  • Possible FH: Same cholesterol threshold PLUS family history of:
    • MI before age 50 in a second-degree relative, or before age 60 in a first-degree relative, OR
    • Total cholesterol >7.5 mmol/L in a first- or second-degree relative

C. US MEDPED Program (Make Early Diagnosis - Prevent Early Deaths)

Uses age-specific and degree-of-relatedness-specific total cholesterol and LDL-C cut-offs. The thresholds are progressively lower the closer the genetic relationship to a known FH index case - a first-degree relative of an FH proband needs a lower LDL-C to qualify than someone from the general population, reflecting the prior probability of inheritance.
Practical note: The DLCN and Simon Broome criteria are the most widely used in clinical practice. Elevated LDL-C alone is often not sufficient for diagnosis due to phenotypic overlap with polygenic hypercholesterolemia; family history substantially increases diagnostic certainty.

Step 5 - Genetic Testing

Genetic testing is increasingly favored and in some settings required. The causal genes are:
GeneInheritanceFrequencyMechanism
LDLRSemidominant80-90%>2000 loss-of-function mutations impair LDL uptake
APOBSemidominant5-10%R3500Q missense reduces LDL-receptor binding
PCSK9Semidominant<2%Gain-of-function mutations increase LDLR degradation
LDLRAP1Recessive<1%Impairs LDLR recycling (causes autosomal recessive FH)
When to prioritize genetic testing:
  • LDL-C >8 mmol/L (pathogenic variant found in >95% of cases)
  • To definitively confirm diagnosis and enable cascade screening
  • When insurance/payer requires genetic confirmation before approving PCSK9 inhibitors
  • Pediatric cases where early treatment decisions are needed
Important limitation: A negative genetic panel does not exclude FH. Up to 30-70% of patients with clinically diagnosed FH (by scoring criteria) may not have an identifiable mutation on current panels - this can reflect polygenic hypercholesterolemia or undiscovered variants.

Step 6 - Distinguish Heterozygous vs. Homozygous FH

FeatureHeterozygous FHHomozygous FH
Prevalence~1 in 250~1 in 500,000
LDL-C190-400 mg/dL>400 mg/dL (often >600)
ASCVD onsetMen: 30s-40s; Women: 40s-50sChildhood
XanthomasAppear 2nd-3rd decadeInfancy/childhood, sometimes at birth
LDLR activity~50% residual<2% (receptor-negative) or 2-25% (receptor-defective)
Aortic stenosisUncommonCan occur from supravalvular cholesterol deposits
Statin responseGenerally goodPoor; often requires apheresis
Homozygous FH patients are classified by residual LDLR activity measured in skin fibroblasts: receptor-negative patients (<2% activity) rarely survive past the second decade untreated; receptor-defective patients (2-25% activity) develop significant atherosclerosis by age 30.

Step 7 - Screening Strategy

PopulationRecommendation
General childrenUniversal fasting or non-fasting lipid panel at ages 8-11 years
High-risk childrenScreen earlier if family history of LDL-C >190 mg/dL or premature ASCVD (men <55, women <65) in a first-degree relative
AdultsLipid panel by age 20 at the latest
Cascade screeningOnce an index case is identified, screen all first-degree relatives - as an autosomal dominant disorder, 50% of first-degree relatives will be affected
Cascade screening is far more efficient than population screening: biochemical or DNA cascade testing of relatives identifies an FH case in ~50% of those tested, compared to 4 per 1000 in population-wide newborn screening.

Sources: Henry's Clinical Diagnosis and Management by Laboratory Methods, p. 303-304 | Goldman-Cecil Medicine, Chapter 190 | Thompson & Thompson Genetics and Genomics in Medicine, 9th ed., Table C.16.2 | Tietz Textbook of Laboratory Medicine, 7th ed., p. 1180 | Robbins & Kumar Basic Pathology | Harrison's Principles of Internal Medicine, 22nd ed.
This is a shared conversation. Sign in to Orris to start your own chat.